| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |